{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:19:03Z","timestamp":1793758743043,"version":"4.6.1"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010578","name":"Deutsche Gesellschaft f\u00fcr Kardiologie - Herz- und Kreislaufforschung eV","doi-asserted-by":"publisher","award":["DGK07\/2022"],"award-info":[{"award-number":["DGK07\/2022"]}],"id":[{"id":"10.13039\/501100010578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["470188766"],"award-info":[{"award-number":["470188766"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["422681845 \\u2013 SFB 1425"],"award-info":[{"award-number":["422681845 \\u2013 SFB 1425"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.steroids.2023.109291","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T01:44:30Z","timestamp":1691372670000},"page":"109291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Molecular pharmacology of mineralocorticoid receptor antagonists: The role of co-regulators"],"prefix":"10.1016","volume":"199","author":[{"given":"Duygu","family":"Koca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9107-5558","authenticated-orcid":false,"given":"Achim","family":"Lother","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.steroids.2023.109291_b0005","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.steroids.2023.109291_b0010","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.steroids.2023.109291_b0015","doi-asserted-by":"crossref","first-page":"e015042","DOI":"10.1161\/JAHA.119.015042","article-title":"Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure","volume":"9","author":"Wirtz","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.steroids.2023.109291_b0020","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12872-016-0425-x","article-title":"Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis","volume":"16","author":"Berbenetz","year":"2016","journal-title":"BMC Cardiovasc. Disord."},{"issue":"1","key":"10.1016\/j.steroids.2023.109291_b0025","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol."},{"issue":"2","key":"10.1016\/j.steroids.2023.109291_b0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.steroids.2023.109291_b0035","doi-asserted-by":"crossref","first-page":"T35","DOI":"10.1530\/JOE-16-0669","article-title":"30 Years of the mineralocorticoid receptor: mineralocorticoid receptor and NaCl transport mechanisms in the renal distal nephron","volume":"234","author":"Shibata","year":"2017","journal-title":"J. Endocrinol."},{"issue":"13","key":"10.1016\/j.steroids.2023.109291_b0040","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1111\/bph.15808","article-title":"Emerging fields for therapeutic targeting of the aldosterone-mineralocorticoid receptor signaling pathway","volume":"179","author":"Lother","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.steroids.2023.109291_b0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.kisu.2021.11.001","article-title":"Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms","volume":"12","author":"Bauersachs","year":"2022","journal-title":"Kidney Int. Suppl."},{"issue":"13","key":"10.1016\/j.steroids.2023.109291_b0050","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1111\/bph.15734","article-title":"The mineralocorticoid receptor in chronic kidney disease","volume":"179","author":"Barrera\u2010Chimal","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"13","key":"10.1016\/j.steroids.2023.109291_b0055","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1111\/bph.15719","article-title":"Approaches towards tissue-selective pharmacology of the mineralocorticoid receptor","volume":"179","author":"Clarisse","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"20","key":"10.1016\/j.steroids.2023.109291_b0060","doi-asserted-by":"crossref","first-page":"12592","DOI":"10.3390\/ijms232012592","article-title":"Importance of micromilieu for pathophysiologic mineralocorticoid receptor activity-when the mineralocorticoid receptor resides in the wrong neighborhood","volume":"23","author":"Griesler","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.steroids.2023.109291_b0065","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1111\/bph.15746","article-title":"Alvarez de la Rosa D","volume":"179","author":"Grossmann","year":"2022","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.steroids.2023.109291_b0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1677\/JME-08-0093","article-title":"Structure-function relationships in the mineralocorticoid receptor","volume":"41","author":"Pippal","year":"2008","journal-title":"J. Mol. Endocrinol."},{"issue":"2","key":"10.1016\/j.steroids.2023.109291_b0075","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.mce.2011.07.035","article-title":"Structural determinants of ligand binding to the mineralocorticoid receptor","volume":"350","author":"Huyet","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"issue":"4812","key":"10.1016\/j.steroids.2023.109291_b0080","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.3037703","article-title":"Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor","volume":"237","author":"Arriza","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.steroids.2023.109291_b0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0014-5793(99)01667-1","article-title":"Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors","volume":"464","author":"Hellal-Levy","year":"1999","journal-title":"FEBS Lett."},{"issue":"9","key":"10.1016\/j.steroids.2023.109291_b0090","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1096\/fj.15-274266","article-title":"Cistrome of the aldosterone-activated mineralocorticoid receptor in human renal cells","volume":"29","author":"Le Billan","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.steroids.2023.109291_b0095","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1210\/me.2009-0032","article-title":"Structural and functional characterization of the interdomain interaction in the mineralocorticoid receptor","volume":"23","author":"Pippal","year":"2009","journal-title":"Mol. Endocrinol."},{"issue":"7","key":"10.1016\/j.steroids.2023.109291_b0100","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41574-020-0349-5","article-title":"Nuclear receptor crosstalk - defining the mechanisms for therapeutic innovation","volume":"16","author":"De Bosscher","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1-2","key":"10.1016\/j.steroids.2023.109291_b0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.mce.2012.12.014","article-title":"How glucocorticoid receptors modulate the activity of other transcription factors: a scope beyond tethering","volume":"380","author":"Ratman","year":"2013","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.steroids.2023.109291_b0110","doi-asserted-by":"crossref","unstructured":"Fettweis G, Johnson TA, Almeida-Prieto B, Presman DM, Hager GL, de la Rosa DA. The mineralocorticoid receptor forms higher order oligomers upon DNA binding. bioRxiv: the preprint server for biology. 2023.","DOI":"10.1101\/2023.01.26.525752"},{"issue":"1","key":"10.1016\/j.steroids.2023.109291_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227520","article-title":"Beyond the heterodimer model for mineralocorticoid and glucocorticoid receptor interactions in nuclei and at DNA","volume":"15","author":"Pooley","year":"2020","journal-title":"PLoS One"},{"issue":"26","key":"10.1016\/j.steroids.2023.109291_b0120","doi-asserted-by":"crossref","first-page":"12480","DOI":"10.1073\/pnas.92.26.12480","article-title":"Steroid receptor heterodimerization demonstrated in vitro and in vivo","volume":"92","author":"Liu","year":"1995","journal-title":"PNAS"},{"key":"10.1016\/j.steroids.2023.109291_b0125","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1210\/en.2018-00819","article-title":"Glucocorticoid Receptor-Tethered Mineralocorticoid Receptors Increase Glucocorticoid-Induced Transcriptional Responses","volume":"160","author":"Rivers","year":"2019","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.steroids.2023.109291_bib528","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1530\/JME-15-0002","article-title":"Interaction between the trout mineralocorticoid and glucocorticoid receptors in vitro","volume":"55","author":"Kiilerich","year":"2015","journal-title":"J. Mol. Endocrinol."},{"issue":"10","key":"10.1016\/j.steroids.2023.109291_b0130","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrendo.2012.100","article-title":"Nuclear receptor coregulators: modulators of pathology and therapeutic targets","volume":"8","author":"Lonard","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.steroids.2023.109291_b0135","doi-asserted-by":"crossref","first-page":"T23","DOI":"10.1530\/JOE-17-0060","article-title":"Coregulators as mediators of mineralocorticoid receptor signalling diversity","volume":"234","author":"Fuller","year":"2017","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.steroids.2023.109291_b0140","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/mend.15.9.0689","article-title":"A new human MR splice variant is a ligand-independent transactivator modulating corticosteroid action","volume":"15","author":"Zennaro","year":"2001","journal-title":"Mol. Endocrinol."},{"issue":"1","key":"10.1016\/j.steroids.2023.109291_b0145","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1146\/annurev-med-051812-145316","article-title":"Nuclear receptor coactivators: master regulators of human health and disease","volume":"65","author":"Dasgupta","year":"2014","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.steroids.2023.109291_b0150","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1126\/science.286.5443.1368","article-title":"Activation of PPARgamma coactivator-1 through transcription factor docking","volume":"286","author":"Puigserver","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.steroids.2023.109291_b0155","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa083","article-title":"Nuclear Receptor Coactivators (NCOAs) and Corepressors (NCORs) in the Brain","volume":"161","author":"Sun","year":"2020","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.steroids.2023.109291_b0200","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1124\/mol.65.3.761","article-title":"DAXX, FLASH, and FAF-1 modulate mineralocorticoid and glucocorticoid receptor-mediated transcription in hippocampal cells\u2013toward a basis for the opposite actions elicited by two nuclear receptors?","volume":"65","author":"Obradovi\u0107","year":"2004","journal-title":"Mol. Pharmacol."},{"issue":"4\u20135","key":"10.1016\/j.steroids.2023.109291_bib527","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jsbmb.2004.04.007","article-title":"Modulation of transcriptional sensitivity of mineralocorticoid and estrogen receptors","volume":"91","author":"Wang","year":"2004","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"6","key":"10.1016\/j.steroids.2023.109291_b0160","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/me.2004-0537","article-title":"The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms","volume":"19","author":"Hultman","year":"2005","journal-title":"Mol. Endocrinol."},{"issue":"17","key":"10.1016\/j.steroids.2023.109291_b0195","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1093\/nar\/gkt581","article-title":"Mineralocorticoid receptor interaction with SP1 generates a new response element for pathophysiologically relevant gene expression","volume":"41","author":"Meinel","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.steroids.2023.109291_b0185","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/me.2004-0331","article-title":"The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions","volume":"19","author":"Pascual-Le Tallec","year":"2005","journal-title":"Mol. Endocrinol."},{"issue":"3","key":"10.1016\/j.steroids.2023.109291_b0215","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1074\/jbc.M607741200","article-title":"Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9","volume":"282","author":"Yokota","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.steroids.2023.109291_b0250","article-title":"Modulation of transcriptional mineralocorticoid receptor activity by casein kinase 2","volume":"7","author":"Ruhs","year":"2017","journal-title":"Sci. Rep.-UK"},{"issue":"8","key":"10.1016\/j.steroids.2023.109291_b0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136801","article-title":"Histone Deacetylase 3 and 4 Complex Stimulates the Transcriptional Activity of the Mineralocorticoid Receptor","volume":"10","author":"Lee","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.steroids.2023.109291_b0175","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/en.2017-00095","article-title":"Interaction of the Mineralocorticoid Receptor With RACK1 and Its Role in Aldosterone Signaling","volume":"158","author":"Kuppusamy","year":"2017","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.steroids.2023.109291_b0220","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1210\/me.2003-0299","article-title":"Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: Implication of small ubiquitin-related modifier 1 modification","volume":"17","author":"Pascual-Le Tallec","year":"2003","journal-title":"Mol. Endocrinol."},{"issue":"11","key":"10.1016\/j.steroids.2023.109291_b0190","doi-asserted-by":"crossref","first-page":"8084","DOI":"10.1074\/jbc.M109.053371","article-title":"NF-YC Functions as a Corepressor of Agonist-bound Mineralocorticoid Receptor","volume":"285","author":"Murai-Takeda","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.steroids.2023.109291_b0225","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41440-022-00859-7","article-title":"Lysine-specific demethylase 1 as a corepressor of mineralocorticoid receptor","volume":"45","author":"Kohata","year":"2022","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.steroids.2023.109291_bib526","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41440-020-00562-5","article-title":"CASZ1b is a novel transcriptional corepressor of mineralocorticoid receptor","volume":"44","author":"Yokota","year":"2021","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.steroids.2023.109291_b0210","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1530\/JME-14-0078","article-title":"GEMIN4 functions as a coregulator of the mineralocorticoid receptor","volume":"54","author":"Yang","year":"2015","journal-title":"J. Mol. Endocrinol."},{"issue":"10","key":"10.1016\/j.steroids.2023.109291_b0170","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1096\/fj.13-242479","article-title":"Identification and characterization of a ligand-selective mineralocorticoid receptor coactivator","volume":"28","author":"Rogerson","year":"2014","journal-title":"FASEB J."},{"issue":"9","key":"10.1016\/j.steroids.2023.109291_b0165","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1210\/me.2014-1101","article-title":"Use of phage display to identify novel mineralocorticoid receptor-interacting proteins","volume":"28","author":"Yang","year":"2014","journal-title":"Mol. Endocrinol."},{"issue":"46","key":"10.1016\/j.steroids.2023.109291_b0180","doi-asserted-by":"crossref","first-page":"46087","DOI":"10.1074\/jbc.M306219200","article-title":"The scaffolding protein RACK1 interacts with androgen receptor and promotes cross-talk through a protein kinase C signaling pathway","volume":"278","author":"Rigas","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.steroids.2023.109291_b0235","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCRESAHA.113.301071","article-title":"Histone deacetylase inhibition attenuates transcriptional activity of mineralocorticoid receptor through its acetylation and prevents development of hypertension","volume":"112","author":"Lee","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.steroids.2023.109291_b0240","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.667990","article-title":"Posttranslational Modifications of the Mineralocorticoid Receptor and Cardiovascular Aging","volume":"8","author":"Gadasheva","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"5","key":"10.1016\/j.steroids.2023.109291_b0245","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.freeradbiomed.2012.06.028","article-title":"Modulation of transcriptional mineralocorticoid receptor activity by nitrosative stress","volume":"53","author":"Ruhs","year":"2012","journal-title":"Free Radic. Biol. Med."},{"issue":"17","key":"10.1016\/j.steroids.2023.109291_b0255","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1021\/ja01574a058","article-title":"Steroidal Lactones","volume":"79","author":"Cella","year":"1957","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.steroids.2023.109291_b0260","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"39","key":"10.1016\/j.steroids.2023.109291_b0265","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.steroids.2023.109291_b0270","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int. J. Cardiol."},{"issue":"13","key":"10.1016\/j.steroids.2023.109291_b0275","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"Suppl 2","key":"10.1016\/j.steroids.2023.109291_b0280","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1093\/ajhp\/61.suppl_2.S14","article-title":"Integrating traditional and emerging treatment options in heart failure","volume":"61","author":"Nolan","year":"2004","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"2","key":"10.1016\/j.steroids.2023.109291_b0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193380","article-title":"Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion","volume":"13","author":"Bamberg","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.steroids.2023.109291_b0520","doi-asserted-by":"crossref","first-page":"105859","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.steroids.2023.109291_b0495","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cts.12705","article-title":"Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study","volume":"13","author":"Whittaker","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.steroids.2023.109291_b0390","article-title":"Pharmacological Profile of KBP-5074, a Novel NonSteroidal Mineralocorticoid Receptor Antagonist for the Treatment of Cardiorenal Diseases","volume":"3","author":"Chow","year":"2017","journal-title":"J. Drug Res. Dev."},{"issue":"8","key":"10.1016\/j.steroids.2023.109291_b0405","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94\u20138862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"issue":"2","key":"10.1016\/j.steroids.2023.109291_b0410","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"issue":"23","key":"10.1016\/j.steroids.2023.109291_b0450","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.steroids.2023.109291_b0500","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","article-title":"Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites","volume":"29","author":"Gardiner","year":"1989","journal-title":"J. Clin. Pharmacol."},{"issue":"19","key":"10.1016\/j.steroids.2023.109291_b0505","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/01.CIR.0000071081.35693.9A","article-title":"Eplerenone: cardiovascular protection","volume":"107","author":"Brown","year":"2003","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.steroids.2023.109291_b0340","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41440-020-00570-5","article-title":"Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism","volume":"44","author":"Satoh","year":"2021","journal-title":"Hypertens. Res."},{"issue":"4","key":"10.1016\/j.steroids.2023.109291_b0515","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s13318-023-00837-5","article-title":"Pharmacokinetics and Drug-Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo","volume":"48","author":"Wang","year":"2023","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.steroids.2023.109291_b0510","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cpdd.263","article-title":"Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94\u20138862) in Individuals With Renal Impairment","volume":"5","author":"Heinig","year":"2016","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.steroids.2023.109291_b0205","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1677\/jme.0.0310573","article-title":"Determinants of spironolactone binding specificity in the mineralocorticoid receptor","volume":"31","author":"Rogerson","year":"2003","journal-title":"J. Mol. Endocrinol."},{"issue":"10","key":"10.1016\/j.steroids.2023.109291_b0345","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/1873-3468.13746","article-title":"Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150)","volume":"594","author":"Takahashi","year":"2020","journal-title":"FEBS Lett."},{"issue":"36","key":"10.1016\/j.steroids.2023.109291_b0285","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.steroids.2023.109291_b0525","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1440-1681.2004.04079.x","article-title":"Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor","volume":"31","author":"Rogerson","year":"2004","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"1","key":"10.1016\/j.steroids.2023.109291_b0300","article-title":"A novel mineralocorticoid receptor antagonist, 7,3',4'-trihydroxyisoflavone improves skin barrier function impaired by endogenous or exogenous glucocorticoids","volume":"11","author":"Lee","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.steroids.2023.109291_b0295","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.3390\/ijms24032439","article-title":"Novel 1,4-dihydropyridine derivatives as mineralocorticoid receptor antagonists","volume":"24","author":"P\u00e9rez-Gordillo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.steroids.2023.109291_b0290","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1073\/pnas.95.6.2973","article-title":"Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists","volume":"95","author":"Fejes-T\u00f3th","year":"1998","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.steroids.2023.109291_b0420","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.steroids.2023.109291_b0305","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.steroids.2023.109291_b0310","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.steroids.2023.109291_b0315","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.steroids.2023.109291_b0320","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ehjcvp\/pvw016","article-title":"Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives","volume":"3","author":"Pitt","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"7","key":"10.1016\/j.steroids.2023.109291_b0325","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/CIRCRESAHA.118.312156","article-title":"Treatment of Resistant and Refractory Hypertension","volume":"124","author":"Acelajado","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.steroids.2023.109291_b0330","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijcard.2016.12.158","article-title":"A meta-analysis of add-on use of spironolactone in patients with resistant hypertension","volume":"233","author":"Zhao","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"10008","key":"10.1016\/j.steroids.2023.109291_b0335","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.steroids.2023.109291_b0350","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5551\/jat.63382","article-title":"A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL\/6 Mice","volume":"30","author":"Munkhjargal","year":"2023","journal-title":"J. Atheroscler. Thromb."},{"issue":"7","key":"10.1016\/j.steroids.2023.109291_b0355","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study","volume":"33","author":"Ito","year":"2019","journal-title":"J. Hum. Hypertens."},{"issue":"1","key":"10.1016\/j.steroids.2023.109291_b0360","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.steroids.2023.109291_b0365","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/j.steroids.2023.109291_b0370","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.steroids.2023.109291_b0380","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/bcp.13562","article-title":"Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator","volume":"84","author":"Erlandsson","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.steroids.2023.109291_b0385","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1111\/cts.13377","article-title":"Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial","volume":"15","author":"Squire","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.steroids.2023.109291_b0395","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.604928","article-title":"The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury","volume":"12","author":"Jaisser","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.steroids.2023.109291_b0400","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.steroids.2023.109291_b0415","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.steroids.2023.109291_b0425","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.yjmcc.2018.06.008","article-title":"Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice","volume":"121","author":"Bonnard","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"5","key":"10.1016\/j.steroids.2023.109291_b0430","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","article-title":"Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy","volume":"67","author":"Grune","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"2","key":"10.1016\/j.steroids.2023.109291_b0435","doi-asserted-by":"crossref","first-page":"e21314","DOI":"10.1096\/fj.202002043RR","article-title":"Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells","volume":"35","author":"Le Billan","year":"2021","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.steroids.2023.109291_b0440","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"31","key":"10.1016\/j.steroids.2023.109291_b0445","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur. Heart J."},{"issue":"24","key":"10.1016\/j.steroids.2023.109291_b0455","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.steroids.2023.109291_b0460","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.steroids.2023.109291_b0465","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1161\/CIRCULATIONAHA.121.053660","article-title":"Letter by Lother et al Regarding Article, \u201cFinerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes\u201d","volume":"144","author":"Lother","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.steroids.2023.109291_b0470","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.559673","article-title":"Improved Glucocorticoid Receptor Ligands: Fantastic Beasts, but How to Find Them?","volume":"11","author":"Van Moortel","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.steroids.2023.109291_b0475","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ando.2018.03.004","article-title":"Glucocorticoid receptor modulators","volume":"79","author":"Meijer","year":"2018","journal-title":"Ann. Endocrinol."},{"key":"10.1016\/j.steroids.2023.109291_b0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","article-title":"Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment","volume":"186","author":"Patel","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.steroids.2023.109291_b0485","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pharmthera.2018.05.002","article-title":"Towards optimization of estrogen receptor modulation in medicine","volume":"189","author":"Val\u00e9ra","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.steroids.2023.109291_b0490","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0092-8674(00)81717-1","article-title":"The structural basis of estrogen receptor\/coactivator recognition and the antagonism of this interaction by tamoxifen","volume":"95","author":"Shiau","year":"1998","journal-title":"Cell"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X23001198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X23001198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:51:22Z","timestamp":1778658682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X23001198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":108,"alternative-id":["S0039128X23001198"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2023.109291","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular pharmacology of mineralocorticoid receptor antagonists: The role of co-regulators","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2023.109291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109291"}}